Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Clinical trial NCT00687596 · TERMINATED
Trial details
- NCT number
- NCT00687596
- Sponsor
- Taiho Oncology, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-08-01
- Primary completion
- 2010-05-10
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.